# ZELTIQ Aesthetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zeltiq-aesthetics

- Industry: Medical Devices & Equipment
- Headquarters: Pleasanton, US
- Website: www.coolsculpting.com
- Total disclosed funding: $78M
- Latest round: Series D (Jun 2, 2010)
- Investors on record: 4

## About

ZELTIQ Aesthetics, Inc. specializes in non-invasive body contouring solutions, utilizing innovative technologies such as CoolSculpting® and CoolTone® to effectively address fat reduction and muscle toning for consumers and clinics.Founded in 2005 and headquartered in Pleasanton, US, ZELTIQ Aesthetics, Inc. focuses on aesthetic treatments. The company was acquired by Allergan Inc. in April 2017 for USD 2.475 billion, following a successful initial public offering in October 2011 that raised USD 91 million. The firm has completed six deals to date, with their latest funding round being a Trade Sale that occurred on 19th October 2011, raising a total of USD 2,475 mn.ZELTIQ Aesthetics offers non-invasive body contouring solutions, primarily through CoolSculpting® and CoolTone®. CoolSculpting® uses controlled cooling technology to eliminate targeted fat cells in areas like the abdomen and thighs. CoolTone® provides muscle stimulation via electromagnetic energy, enhancing muscle tone in the abdomen, buttocks, and thighs. These products are marketed to individual consumers and healthcare professionals and are available in the US, Canada, and select European and Asian locations.In the most recent fiscal year of 2016, ZELTIQ Aesthetics reported a revenue of USD 354.20 mn, with an EBITDA of USD 16.87 mn. The company’s revenue model is based on a direct-to-consumer approach, where individuals pay for treatment sessions, often facilitated through partnerships with aesthetic clinics, providing their technologies to a wider client base.ZELTIQ Aesthetics aims to further expand its market reach following its acquisition by Allergan Inc. The company is focused on launching new products and enhancing its service offerings. The recent acquisition funding will be used to support product development and market expansion initiatives. Specific geographic regions targeted for expansion include new markets in both Europe and Asia, contributing to growth strategies post-2017.

## Funding rounds

- Series D, Jun 2, 2010, $25M — Advanced Technology Ventures, Frazier Healthcare Partners, Venrock, Aisling Capital
- Series C, Apr 18, 2008, $25M — Venrock
- Series B, Oct 29, 2007, $20M — Advanced Technology Ventures, Frazier Healthcare Partners
- Series A, Mar 15, 2006, $7.5M — Advanced Technology Ventures, Frazier Healthcare Partners

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series A, Series B, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C, Series D
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series D